- October 13 - 14, 2020
10:30 AM - 3:30 PM ET
- Organized By:
ABOUT THIS EVENT
The U.S. Food and Drug Administration (FDA, the Agency, or we) is hosting a public meeting entitled, "2020 Public Meeting of the National Antimicrobial Resistance Monitoring System." The purpose of this meeting is to discuss the progress the National Antimicrobial Resistance Monitoring System (NARMS) has made since the last public meeting in 2017, and to present the NARMS Strategic Plan: 2021-2025.
The public meeting will be hosted via a live virtual webcast on Tuesday, October 13 (10:30 a.m. to 4:00 p.m. ET) and Wednesday, October 14 (9:30 a.m. to 3:30 p.m. ET), 2020. Advance registration is required to attend the virtual NARMS Public Meeting.
To register for the public meeting, please provide complete contact information for each attendee, including name, title, affiliation, address, email, and telephone number to Kelly Covington, email@example.com, by Friday, October 2, 2020, 4:00 p.m. ET. A webcast link will be emailed to attendees one week prior to the scheduled meeting – on October 6, 2020.
Request to Make an Oral Presentation
During registration you may indicate if you wish to present during the public comment session on Wednesday, October 14th, and which topic(s) you wish to address. We will do our best to accommodate requests to make public comments. Individuals and organizations with common interests are urged to consolidate or coordinate their presentations and request time for a joint presentation. All requests to make oral presentations must be received by the close of registration on Friday, October 2, 2020, 4:00 p.m. ET. Following the close of registration, we will determine the amount of time allotted to each presenter and the approximate time each oral presentation is to begin, and will select and notify participants by Tuesday, October 6, 2020. If selected for presentation, any presentation materials must be emailed to Claudine.Kabera@fda.hhs.gov no later than 4:00 p.m. on Friday, October 9, 2020. No commercial or promotional material will be permitted to be presented or distributed at the public meeting.
The FDA is accepting public comments August 19, 2020 through November 13, 2020. To electronically submit comments to the docket, visit https://www.regulations.gov and type FDA-2020-N-1764 in the search box. For assistance in submitting electronic comments, please see regulations.gov/help. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov.
Due to the COVID-19 pandemic, Dockets Management Staff is receiving USPS mail intermittently. Therefore, electronic submissions are preferred. To submit comments to the docket by mail, use the following address: Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. Be sure to include docket number FDA-2020-N-1764 on each page of your written comments. Received comments filed in a timely manner will be placed in the docket and, except for those submitted as "Confidential Submissions," publicly viewable at https://www.regulations.gov.
To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states "THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION." The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as "confidential." Any information marked as "confidential" will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015.
For access to the docket to read the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the "Search" box and follow the prompts.
A transcript of the meeting will be made available within 30 days after the meeting. It will be accessible at https://www.regulations.gov under docket number FDA-2020-N-1764. A link to the transcript will also be available on this webpage.
Updated November 13, 2020: Due to technical issues, there will be a delay in the release of the recording and transcript for the NARMS Public Meeting that was held October 13-14, 2020. We apologize for the inconvenience. Please check back here next month for the recording and transcript.
FOR MORE INFORMATION:
|2020 NARMS Public Meeting Agenda||pdf (153.87 KB)|